7/102 sources · 2 publishersUpdated Oct 27, 12:12 UTC
JPMorgan upgrades Genmab to Overweight and raises price target to DKK3,500
JPMorgan upgraded Genmab A/S to Overweight from Neutral and lifted its price target to DKK3,500, up from DKK2,050. The brokerage expects a positive Phase III readout for petosemtamab with an overall response rate of at least 40% and raised the drug’s peak sales forecast to $5 billion. It also increased peak‑sales forecasts for Rina‑S and Epkinly and adjusted its revenue and EPS outlooks for 2026‑2030.
Why it matters
JPMorgan’s upgrade and higher price target signal a bullish outlook that could lift Genmab’s share price, while the raised sales forecasts suggest higher future cash flows if the trials succeed.
Key facts
- 1Genmab was upgraded to Overweight from Neutral by JPMorgan. investing.com
- 2JPMorgan raised the price target to DKK3,500 from DKK2,050. investing.com
- 3The firm expects petosemtamab’s Phase III interim readout to show an overall response rate of at least 40%. investing.com
- 4JPMorgan increased the unadjusted peak sales forecast for petosemtamab to $5 billion from $2.5 billion. investing.com
- 5Peak‑sales forecasts were also raised to $4 billion for Rina‑S (from $3.4 billion) and to $2.5 billion for Epkinly (from $1.4 billion). finance.yahoo.com
- 6JPMorgan lifted its 2027 adjusted earnings‑per‑share forecast to $15.48 from $11.38. finance.yahoo.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.